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1. Introduction 
Osteoporosis is a metabolic skeletal disease characterized by low bone mineral density 
(BMD), damage of bone microstructure, bone fragility resulting in increase risk of bone 
fractures. Epidemiologic data are continuously showing rising number of newly diagnostic 
patients with osteoporosis. The expected number of bone fractures due to osteoporosis is to 
be 6. 26 million in 2050, growth from 1. 56 million in 1990 (Payer et al., 2007). The fractures 
are usually localized in lumbar spine (or other vertebra), hip and forearm (wrist), The most 
serious is the fracture of proximal femur (hip), beacuse approximately 20% of  these pateints 
die within one year after the fracture and almost 80% become dependent on some kind of 
care (Cooper, 1997). The precise number of vertebral pathological fractures is difficult to 
assess, because many of these fractures are asymptomatic. Despite this they increase 
mortality by 23% (Cooper, 2007). The wrist fracture do not increase the mortality. The 
incidence is much more frequent in women than in men (4 : 1). The increased frequency of 
osteoporosis is partly due to increase in absolute number of new patients  and partly due to 
continualy improving diagnostic procedures. The new generation of equipments and 
laboratory technics more precisely identify patients with bone loss. In the same time  
improvement in public information leads to increasing number of densitometric 
examinations.  
Bone tissue is highly active metabolic organ. The bone tissue remodelation  (formation of 
new bone tissue and its degradation) is active and continual process. Very important role in 
regulation of this process have hormones (estrogens and androgens). The mostly 
understood and resolved is postmenopausal osteoporosis and the most important risk 
groups and factors were identified (Rizzoli et al., 2005).  
Cancer patients, especially those with „hormone dependent“ disease (breast cancer, prostate 
cancer) or those with treatment interfering in hormonal metabolism (breast cancer, prostate 
cancer, thyroid cancer, ovarian cancer, germ cell tumor and others) are in inceased risk of 
disease  or therapy induced osteoporosis. There are increased numbers of information and 
references on this topic.  
The most advanced are data on patients with breast cancer, particularly those with early 
breast cancer (EBC) on adjuvant aromatase inhibitors (AI) therapy.  
Women with breast cancer, especially those receiving aromatase inhibitors are at higher risk 
for bone loss and fracture. Postmenopausal women may already have multiple risk factors 
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for fracture, and breast cancer therapies compound these risk (Hadji & Bundred, 2007). 
Fractures can have serious clinical consequences including need for major surgery, 
increased morbidity and mortality, increased cost of disease management, and reduced 
quality of the life for patients (Body, 2011). 
Additional group of patients in risk are those with prostate cancer on hormonal therapy, 
thyroid cancer (TC) after total or nearly total thyroidectomy on whole-life substitution 
therapy  by oral thyroxine (T4) and patients with germ cell tumors (GCT) after surgery and 
radiotherapy and/or chemotherapy. 
We have started to measure BMD in patients with breast cancer (BC), prostate cancer, 
thyroid cancer (TC) and germ cell tumors few years ago. Some of the results are nearly 
mature and ready to be publish (EBC, TC, GCT) others need more patients and time of 
follow-up (PC). 
2. Breast cancer 
2.1 Introduction 
Postmenopausal breast cancer patients are in high risk of osteoporosis in many reasons – 
primary diagnosis of breast cancer, then side-effects of anticancer therapy, postmenopausal 
status. These factors mean not just elevated risk of bone loss, osteoporosis, but especially 
risk of patological fractures. Many of postmenopausal breast cancer patients, especially 
those with early stage, with aromatase inhibitors (AI) adjuvant therapy have very good 
prognosis. The elevated risk of osteoporosis can lead to patological fractures which may  
markedly worsen their quality of life (Coleman et al., 2008). 
Antagonizing estrogen in hormone-dependent breast cancer is well-known method of 
reducing tumor growth. Five years of treatment with tamoxifen, an antiestrogen or selective 
estrogen-receptor modulator (SERM), has been shown to reduce the risk of recurrence and 
breast cancer mortality by  41% and 34% respectively and is still recommended as one of 
several options for early-stage hormone receptor-positive breast cancer.  
New data from clinical trials comparing third-generation aromatase inhibitors (AI) with 
tamoxifen have confirmed that AI offer significant efficacy and tolerability advantage over 
tamoxifen. Aromatase inhibitors are recommended as adjuvant treatmen for 
postmenopausal women with hormone-receptor positive early breast cancer. The group of 
clinicaly used AI contains non-steroidal AI letrozole and anastrozole and steroidal-AI 
exemestane. The primary mechanism of action of AI is inhibition of aromatase activity. 
Aromatase is the most important enzyme responsible for conversion of androgens to 
estrogens, mainly in tissues outside endocrine system. This is the most important 
mechanism of estrogen production in postmenopausal women. Estrogen production 
blockade influences bone metabolism directly via osteoclastogenesis stimulation. Survival 
extension of osteoclasts is the main mechanism. Cytokines, interleukines 1 and 6, 
osteoprotegerin, bone resorption potentiation, osteocytes and osteoblasts apoptosis are other 
important mechanisms resulting in osteosynthesis inhibiton. AIs also play key role in 
calcium metabolism. Their action influence calcium absorption in small bowel and renal 
elimination. It is very similar to estrogens level decrease after menopause leading to 
postmenopausal osteoporosis (Rizzoli, 2005).  
AIs in breast cancer treatment are used as adjuvant therapy – it means after radical surgery 
in early breast cancer, stages I - III or as palliative therapy of locally advanced or metastatic 
disease. Standard duration of adjuvant hormonal therapy is now 5 years. Recently 
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published  results of large international multicenter clinical studies (including more than 15 
000 pacients) such as ATAC (Howell et al., 2005) and BIG (Coates et al., 2007) have shown 
that adjuvant hormonal therapy using AIs and lasting 5 years is more effective than 
adjuvant therapy using selective estrogen receptor modulators (SERMs), mainly tamoxifen. 
Substudies of these and many other similar studies dealing with bone mineral density 
(BMD) in early breast cancer patients on adjuvant hormonal therapy are consistently 
showing higher decrease of BMD during treatment with AIs than that with tamoxifen. This 
is the reason why regular BMD measurements at the beginning and during AIs adjuvant 
therapy  were  implemented into new recommendations for early breast cancer therapy 
published in July 2007 as results of consensus of panel of most important international 
leaders in the field during 10th St Gallen Conference (Goldhirsch et al., 2007).  
2.2 Patients and methods 
We started regular bone mineral density (BMD) measurement of postmenopausal early 
breast cancer patients treated either with aromatase inhibitors (AIs) or tamoxifen in St. 
Elisabeth Cancer Institute on  September 2005. The most important goal of our study was to 
determine bone mineral density   decrease in early breast cancer patients treated with (AIs). 
We measured BMD at the begining of treatment and during therapy (after one year or two 
depending on initial results) with AIs and a group of patients who have their hormonal 
therapy switched from tamoxifen do AIs for different reasons (intolerance or toxicity).  
As an comparative groups we measured BMD in group of early breast cancer patients 
treated with tamoxifen  and patients after finished hormonal therapy without any anticaner 
therapy, only on regular follow-up. The study is sitll active, in this preliminary evaluation 
we analysed group of 263 consecutive patients with early breast cancer, 42 on active AIs 
therapy - 22 on letrozole on oral daily dose  2,5 mg, 20 on anastrozole on oral daily dose  1 
mg, 72 patients with „switched“ therapy from tamoxifen to AIs, 69 on active tamoxife 
therapy on oral daily dose 20 mg and 80 patients just on follow-up after finishing active 
hormonal treatment. 
In all our patients the BMD measurement was performed on total body densitometer 
Hologic Explorer. We measured and evaluated region of proximal femur and L spine. In 
cases of degenerative changes which overestimated results we measured and evaluated the 
region of forearm. For comparisons we evaluated T score. All patients included in our study 
have measured height, weight, assessed age, duration of menopause, hormonal replacement 
therapy and history of other risk factors and previous fractures. All patients have measured 
calcium  blood  level. We also measured markers of bone turnover, CTX  (CrossLaps - C 
telopeptide of  alfa chain 2(I) colagen) as marker of osteoporosis measured by ELISA 
method and isoensyme of ALP as marker of osteoproduction. In patients with BMD results 
on levels of osteoporosis we made differential diagnostic examinations to exclude secondary 
osteoporosis. This is important especially in patients with breast cancer to exclude bone 
marrow metastases, which are most frequent sites of generalised disease. We used cancer 
markers, RTG, CT, MRI or bone scan - sceletal gamagraphy 
For the statistical analysis we used standard methods of descriptive statistics, test of data 
independence and multiple regression was used to verify influence of separate factors 
especially to exclude possible secondary influences in case of interactive correlation among 
parameters. 
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2.3 Results 
From the whole study group of 263 postmenopausal early breast cancer patients, 114  
patients in the group treated  with AIs (72 of them switched from previous tamoxifen to 
AIs), 69 on tamoxifen therapy and 80 patients without hormonal therapy only on follow-up 
after finishing  hormonal treatment (figure 1). 
 
 
Fig. 1. Patients Characteristics 
We found normal BMD only in 13,31% among all evaluated patients,  43,35% of the whole 
analysed patients had BMD rate in levels of osteoporosis. Analysing the localisations of 
measured osteoporosis we found this in 5,25% in proximal femur, 63,1% in L spine 
and 31,58% in region of the forearm (figure 2) – those were patients with deformations or 
degenerative changes in region of spine, which overestimated the results. 
 
 
Fig. 2. BMD in Patients with Breast Cancer  
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Median of age of the whole group of patients was 61 years. The BMD loss to levels of 
osteoporosis was found in group of patients under 50 years of age in 26%, where 50% of 
them had osteoporosis in region of  L spine, 38% in region of proximal femur and only 13% 
in region of forearm. The rate of osteoporosis was higher in the group of patients older than 
70 years -  73% and most of them had osteoporosis in the region of forearm  – 49%. The 
region of L spine was overestimated by degenerative and deformative changes in this age 
group of patients. Group of patients in age between  50  to 70 years had BMD levels of 
osteoporosis in 34%, most frequently in region of  L spine – 80%. These findings are in 
correlation with many clinical studies confirming rising incidence of osteoporosis with 
rising  age. We confirm influence of menopause duration on osteoporosis as well as negative 
correlation of weight and osteoporosis in our study. All this findings are in consensus with 
literature data. 
We also analysed impact of therapy on BMD loss. In the group of patients with AI therapy 
BMD loss to level of osteoporosis was diagnosed in 43,86% and normal BMD had 13,16% of 
patients, in the group with tamoxifen therapy the rate of osteoporosis  was  30,43% and 
normal BMD had 18,84%  of patients, in the group on follow-up without hormonal therapy 
the rate of osteoporosis was 53,75% and normal BMD had  8,7% of patients. The correlation 
between BMD loss and hormonal therapy was not proven statistically significant despite 
trend of tamoxifen protective effect on BMD maintenance. This was not statistically 
significant - (p=0,0610). In subanalysis, where we correlate BMD loss  only in subgroup of 
patients treated  by AIs at least one year and patients treated less than 1 year or just on 
follow-up without hormonal therapy (figure 3), the difference was statistically significant. 
The rate of BMD loss to level of osteoporosis was 53,13% in the first group and only 40,2% in 
the letter and normal BMD rate was only  3,13% in the first group  versus 16,58% in second 
one -  (p=0,0150). 
 
 
Fig. 3. BMD in Patients with Aromatase Inhibitors Therapy and Others 
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We analysed other risk factors and we found highest rate of patients with diabetes mellitus 
among those risk factors (33 patients) but we did not confirm statistical significant influence 
of diabetes mellitus on  BMD loss  - (p=0,816). 
Correlation of  BMD loss and increase levels of CTX as a marker of bone  resorption was not 
confirmed in our study. 
We tested all above mentioned risk factors statistically also (figure 4) using method of 
multiple linear regression to eliminate potential secondary influences in cross interactions 
among factors. Correlations BMD level to age (p0,0001 and weight (p0,0001) were 
confirmed by multiple linear regression. Borderline statistical significance was shown in 
correlation to AIs therapy (=0,0476). The influence of time from menopause (p=0,3410) 
seemed to be secondary regarding to high correlation to age of patients  (r=0,89, p 0,0001). 
 
 
 
 
 
Fig. 4. Correlation of BMD with Age, Weight and Time from Menopause 
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The rate of pathological fractures was analysed also (figure 5). The most frequent incidence 
was in group of patients with osteoporosis. Wrist fracture was found in 10 patients and 5 
had fractures in region of L spine. In the group of patients with BMD  on level of osteopenia,  
5 patients had pathological fractures, 3 of them were wrist fractures and  2 in region of  L 
spine. There were only 2 pathological fractures in patients with normal BMD levels, both 
were wrist fractures. The  whole group of patients we considered to be too small to make 
statistical analysis of risk factors of pathological fractures.  
The last was the analysis of influence of antiresorptive therapy on BMD changes (figure 6). 
The analysis seemed to be preliminary as in the control group (control BMD measurement 
after 1 year of duration of antiresorptive therapy) were only  53 patients. This did not allow 
us to make relevant statistical analysis, although we found trend toward protective effect of 
antiresorptive therapy in this group of patients.  
 
 
Fig. 5. Patological Fractures Rate 
 
 
Fig. 6. Impact of Antiresorptive Therapy on BMD in patients with Breast Cancer 
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2.4 Discussion 
The AIs are new standard in adjuvant hormonal therapy of early breast cancer 
postmenopausal patients. As the results of many large international multicentre clinical 
trials are more mature and results of substudies focused on BMD loss more and more 
consistant, new standards for BMD examination are evolving. The prognosis of early breast 
cancer patients is continually improving. BMD loss means increasing risk of osteoporosis 
and it means increasing risk of pathological fractures. There are many risks factors for this 
group of patients - age, postmenopausal status, breast cancer, AIs therapy. Adjuvant 
hormonal therapy is one of the most important factors leading to significant improvement in 
patient survival and the same important is quality of life which may be markedly decreased 
by pathological fractures from osteoporosis.  
Identification of all risk factors of origin and progression of osteoporosis as well as exact 
examination procedures to find them is as important as prevention and therapy of BMD 
loss. Generally confirmed risk factors for pathological fractures of osteoporosis in breast 
cancer patients are: 
 
AIs therapy 
T-score  1. 5 
Age  65 years 
Low body mass index (BMI  20 kg/m2) 
Family history of hip fracture 
Personal history of fracture from osteoporosis after age of  50 
Oral corticosteroid  therapy lasting   6 months 
Smoking (in present or in past) 
Table 1. Risk factors for pathological fractures of osteoporosis in breast cancer patients 
In multicenter international clinical trial „ATAC“, where the postmenopausal early breast 
cancer patients were randomised (final design) to AI  anastrozole (A) versus tamoxifen (T) 
showed that after 5 years of therapy (Howell et al., 2005) there were significantly more 
bone fractures on arm A  (11% versus 7% p  0. 001). In clinical trial  „BIG 1-98“ the same 
postmenopausal early breast cancer patients were randomised to AI letrozole (L) versus 
tamoxifen (T). With median of follow-up of  26 months  (Thurliman et al., 2005) there 
were significantly more bone fractures on arm  L (5.7% versus 4.0% p  0. 001). Very 
similar results were reached in the clinical study  „IES“ where the postmenopausal early 
breast cancer patients were randomised to AI exemestane (E) versus tamoxifen (T) and 
with median of follow-up  56 months (Coombes et al., 2007) there were significantly 
more bone fractures on arm  E (7% versus 4. 9% p = 0. 003). In combined clinical study  
„ABCSG-8 and ARNO 95“ the patients were „switched“ after anastrozole (A) therapy to 
tamoxifen (T) vs continuing T therapy. With median of follow-up of 28 months (Jakesz et 
al., 2005) there was similar significant difference against arm A (2% versus 1%  p = 0. 
015). In the clinical study „MA.17“ were the patients after 5 years on tamoxifen (T) 
therapy randomised to „switch“ to anastrozole (A) versus  only follow-up without 
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hormonal treatment. With median of follow-up of 30 months (Goss et al., 2005), there 
were more patients with newly diagnostic  osteoporosis on arm A (8. 1% versus 6. 0% p = 
0. 003), and more bone fractures (5. 6% versus 4. 6%, this difference was however not 
statistically significant  p = 0. 25).  
In comparison of patients on AI anastrozole (A) therapy from the clinical study „ATAC“ to 
their healthy counterparts matched in age, postmenopausal status, with osteopenia, the 
incidence of bone fractures were nearly doubled.  
We confirmed the prognostic importance of age, duration of menopause, AIs treatment in 
comparison to tamoxifen treatment or no therapy in follow-up group in our clinical 
observation. All these results are in concordance with world scientific literature. 
According to WHO and NOF (National Osteoporotic Foundation) guidelines is the value of  
T-score in BMD measurement critical in distribution to normal BMD (T-score  - 1. 0), 
osteopenia (T-score between  – 1. 0 and – 2. 5) and osteoporosis (T-score ≤ - 2.5) (Kanis et al., 
2008). According to international general guidelines is this classification universally 
accepted and it is recognised that with decreasing BMD level the risk of pathological bone 
fractures  is rising. That is why the results and observations of the clinical study NORA 
(National Osteoporosis Risk Assessment) are so interesting. They observed   200 000 
healthy postmenopausal women and found that  82% pathological bone fractures  happened 
in women with  T-score  - 2. 5, which means that they did no have osteoporosis and 52% 
fractures were in women with osteopenia (T-score – 1. 0 to – 2.5).  
All these results and findings confirm the importance of BMD measurement before AIs 
therapy initiation and importance of preventive measurements as components of adjuvant 
AIs therapy as well. Calcium and vitamin D supplementation and appropriate physical 
activity are standard components of these recommendations (Goldhirsch et al., 2007). 
Preventive bisphosphonates application is being evaluated in many running clinical 
studies. Especially zoledronic acid is showing excellent results and it seems to be 
incorporated into standard combination with AIs in adjuvant therapy of postmenopausal 
early breast cancer patients very soon as osteoporosis and bone fracture prevention 
(Gnant et al., 2007).  
There was observed protective effect against bone loss, longer period to bone metastases 
occurence and suspected direct anticancer effect as well. These results will probably lead 
very soon to change today ´s standards and bisphosphonates will be used together with AIs 
in adjuvant therapy of early breast cancer patients (Gnant et al., 2007).  
The influence of antiresorptive therapy on BMD was part of our study as well. This analysis 
is difficult to interpret as our control group (control BMD measurement after 1 year of 
duration of antiresorptive therapy) was very small (only  53 patients) and median of follow-
up very short. This did not allow us to make relevant statistical analysis but we found trend 
toward protective effect of antiresorptive therapy in this group of patients.  
We did not confirm correlation of BMD decrease and CTX elevation. Probably the reason 
was small analysed group of patients and low specificity of CTX as osteoporosis marker 
(S.Špánik & B. Špániková, 2010).  
2.5 Conclusions and future directions 
The most important goal of our study was to confirm the importance of BMD 
measurement and evaluation in group of postmenopausal early breast cancer patients on 
AIs therapy. Even the study group is not very large, all the patients are from single 
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institute and we have  planned to follow-up them throughout the AIs therapy and 
thereafter. Preliminary analysis of our data confirmed significant BMD loss in this group 
of patients. The AIs therapy influence on BMD loss was statistically significant after one 
year of therapy. For more valid data we need more patients and longer time of follow-up. 
Our plan is to continue in evaluation of influence of antiresorptive therapy on BMD as we 
observed trend of protection of BMD. Evaluation of importance of BMD loss for increase 
risk of pathological bone fractures also needs more patients and longer time of follow-up 
(Hadji et al., 2011). 
Our observational study confirmed importance of BMD measurement and evaluation in 
postmenopausal early breast cancer patients on AIs therapy. This is in concordance with 
new recommendations for early breast cancer therapy published in July 2007 as a result of 
consensus conference (10th St Gallen Conference) and other important international 
guidelines. 
3. Testicular cancer  
3.1 Introduction 
Testicular cancer (TC) is still being serious disease although when the patients are correctly 
diagnosed and treated the cure rate is about  90%. Testicular cancer make about 1% of 
malignant tumors in men, the incidence in recent years is going up. The incidence in Slovak 
Republic in 2003 was 7,3/100000 men and during last 30 years has increased almost 5-
times.TC appear mostly in men from 20 to 40 years of lilfe. (D. Ondruš & M. Ondrušová, 
2008). According to international classification more than 95% of TC are germ cell tumors 
(GCT), which are classified into two major subgroups: seminoma and non-seminoma GCT. 
Nonseminomatous GCT comprises approximately 50% of all GCT. Most tumors are mixed, 
consisting of two or more cell types (embryonal carcinoma,  choriocarcinoma, yolk sac 
tumor, teratoma or their mixtures). The rest of  testicular tumors are rare - Leydig cell 
tumors, Sertoli cell tumors, granulosa cell tumors, gonadoblastoma, sarcomas, lymphomas 
and others). 
The diagnosis of GCT is based on clinical picture – painless testicular mass, symptoms of 
epididymitis or orchitis, less frequently occurs testicular pain. 
For pretreatment staging we use ultrasound, computed tomography (CT) of chest, abdomen 
and pelvis and serum tumor markers (alfa-fetoprotein, human chorionic gonadotropin, 
lactate dehydrogenase).  
The standard therapeutic procedure is surgery, radical orchciectomy and retroperitoneal 
lymph node dissection (according to histological type and stage of the disease). Other 
therapeutic options are radiotherapy and chemotherapy (again according to histological 
type and stage of the disease). 
During recent decades the survival rate of patients with testicular cancer or germ cell 
tumors (GCT) has substantially improved. Consequently the long-term side effects of 
treatment of GCT have gained attention, including accelerated bone loss leading to 
increased risk of  osteoporosis. Treatment-related bone loss is well recognized in breast and 
prostate cancer, but there has been little information in long-term survivors from other 
tumors (Marcus et al., 2008). 
We have a large group of GCT patients in our registry at the Department of Urology of St. 
Elisabeth Cancer Institute with a long duration follow-up. It is already known that 
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androgens influence bone modelling and remodelling acting on osteoblasts, osteocytes and 
pluripotent stem cells through androgen receptors. They also act indirectly via estrogen 
receptors. The combined influence of androgens and estrogens is even stronger. We suppose 
that patients after unilateral orchiectomy (OE) or bilateral orchiectomy and consecutive 
radiotherapy and/or chemotherapy should have lower levels of testosterone. Literature 
sources on this issue are scarce and conflicting. There are numerous animal studies proving 
the effect of androgens on bone and also proving much stronger effect of androgen and 
estrogen combination (Ondruš et al., 2007). 
3.2 Patients and methods 
Our aim was to determine BMD and serum bone turnover markers in survivors from GCT. 
We included 719 patients with GCT into the  study. We measured BMD in GCT patients 
from 2005. 
BMD was measured by dual-energy X-ray absorptiometry  using osteodenzitometer Holgic 
Discovery in the lumbar spine and hips. BMD was classified as osteopenia (T score ranging 
from –2, 5 to –1.0) and osteoporosis (T score less than –2. 5). Latter according to WHO 
recommendation for men under 50 years of age we use Z score (comparison of detected 
BMD to healthy bone of comparable age group).  
C-terminal cross-linked telopeptides of type I collagen (CTX) were measured using Enzyme-
Linked Immunoabsorbent Assay (ELISA). Additionally serum total testosterone was 
measured. 
Comparison was made with matched healthy control group from Ministery of health 
registry. Relationships between baseline characteristics (age, treatment type and time 
from orchiectomy) and BMD were assessed using univariate and multivariate analysis 
tools.  
The data was evaluated using Microsoft Excel 2003 software and its built-in statistical 
functions and data analysis tools. We used standard uni-, bi- and multivariate statistical 
methods as appropriate throughout data analysis. Association between two nominal 
variables was tested using the Chi-squared test of independence. Association between an 
interval variable and a nominal one was tested using ANOVA or Kruskal-Wallis test, 
depending on the distribution of the interval variable; in case of a dichotomous variable, t-
test was applied instead of ANOVA and Mann-Whitney test instead of Kruskal-Wallis test. 
A multiple linear regression was performed to test for association between an dependent 
interval variable and several predicting interval variables (Mardiak et al., 2007) 
3.3 Results 
We included 719 patients into  the study (21 – 76 yrs old, median: 39 yrs) who were treated 
for GCT since 1982. In this group, 663 pts (92%) were treated by unilateral orchiectomy (OE) 
and 56 pts (8%) by bilateral OE. The further treatment was radiotherapy of retroperitoneal 
lymph nodes  (RPLND) in 124 pts (17%), chemotherapy in 405 pts (57%), radiotherapy and 
chemotherapy in in 16 pts (2%), the rest 174 pts (24%) did not receive any adjuvant therapy 
(fig. 7). Median time since OE was 6. 5 yrs, average time was 8. 1 yrs. 
We have proved a significant difference between BMD patients with GCT compared to 
the healthy population (p<0.0001) with more osteopenia and osteoporosis in GCT 
patients.  
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Fig. 7. Patients characteristics 
We have made comparisons between the group of GCT patients and the healthy match 
control group according to type of surgery and subsequent therapy (fig. 8) 
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Fig. 8. Comparison of GCT group to healthy match control group 
We made comparison of BMD and the type of orchiectomy (fg. 9) 
 
 
Fig. 9. Comparison of BMD and type of OE 
Comparison was made between the subgroup of patients with unilateral orchiectomy and a 
the subgroup of those treated with bilateral orchiectomy. While the incidence of 
osteoporosis has not proved to be significantly different in the two subgroups (p=0.1725), 
patients treated with bilateral OE have significantly higher incidence of osteopenia 
(p=0.0116). 
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We also made comparisons of BMD of patients with GCT and different types of OE to 
healthy match control group (fig. 10) 
 
 
 
 
 
 
 
Fig. 10. Comparisons of BMD of patients with GCT and different types of OE to the healthy 
match control group 
In a separate comparison of the subgroup of patients treated with bilateral orchiectomy to 
the healthy population we have concluded not only a significantly higher incidence of 
osteoporosis in the former (p<0.0001), but also a significantly higher incidence of osteopenia 
in those patients treated with bilateral OE (p=0.0114). Patients treated with unilateral OE 
compared to the healthy population have a significantly higher incidence of osteoporosis 
(p<0.0001) We also made comparisons of BMD according to time from primary therapy 
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Fig. 11. BMD and median time since OE 
All the most important results are summarized in table 2. 
 
    Total Osteoporosis Osteopenia Normal BMD P value 
     
Number of patients: 719 98 / 14% 296 / 41% 325 / 45%  
      
      
Treatment:   
  Unilateral OE 663 87 / 13% 264 / 40% 312 / 47%  
  Bilateral OE 56 11 / 20% 32 / 57% 13 / 23%  
  Chemotherapy 405 48 / 12% 172 / 42% 185 / 46%  
  Radiotherapy 124 19 / 15% 48 / 39% 57 / 46%  
  Chemo- and Radiotherapy 16 3 / 19% 10 / 63% 3 / 19%  
      
      
Characteristics (Risk Factors):   
  Fractures 98 10 / 10% 47 / 48% 41 / 42%  
    
Demographics:   
  Median age 43,0 39,0 37,0 (<0.0001) 
  Average age 43,8 39,5 37,7 (<0.0001) 
      
      
Baseline Characteristics (medians):   
  Time since OE 702 9,0 6,0 5,0 (0.0049) 
  Testosterone (nmol/l) 478 16,8 16,6 16,3 (0.6887) 
  Free Testosterone (pg/ml) 132 7,0 8,3 8,3 (0.3526) 
  CTX (scale 1: ng/ml) 137 0,4 0,5 0,4 (0.5545) 
  CTX (scale 2: pM) 287 3341,0 4175,5 3941,5 (0.2101) 
  LH 4,6 4,6 4,6 (0.3602) 
Table 2. Patients with GST – characteristics and results 
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3.4 Conclusions and future directions 
 We have proved a significant difference between BMD patients with GCT and healthy 
population (p<0.0001).  
 The incidence of osteoporosis is significantly higher in patients with GCT compared to 
the healthy population (p<0.0001).  
 While the incidence of osteoporosis has not proved to be significantly different in the 
two subgroups (p=0.1725), patients treated with bilateral OE have significantly higher 
incidence of osteopenia (p=0.0116).  
 Comparing the minimum T-score between the two subgroups, we have concluded 
significantly lower median T-score in patients with bilateral OE compared to those 
treated with unilateral OE (p=0.0148).  
 We have come to the conclusion of no significant association between BMD and type of 
therapy in patients with GCT (p=0.287).  
 There is no significant association between BMD and CTX level (p=0.1600).  
 Correlation between T-score and  testosterone  also free testosterone level in  
patients with GCT, the correlation coefficient of 0.0881, did not prove as significant 
(p=0.3263).  
We did not find any significant differences between GCT and matched control data 
regarding the incidence of osteopenia and bone turnover marker, but the incidence of 
osteoporosis was considerably higher in GCT patients. The incidence of osteopororsis 
appeared to increase with age and to slightly correlate with time since OE, particularly after 
10 years following OE. Type of therapy did not prove to have significant impact on the 
appearance of osteoporosis. Serum testosterone level did not correlate with BMD. We 
recommend BMD measurement and evaluation in GCT patients after therapy (Ondrušová et 
al., 2009). 
4. Bone mineral density in thyroid cancer (TC) patients on suppresive 
therapy after total thyroidectomy 
4.1 Introduction 
Thyroid cancer (TC) is another type of cancer which should be associated with decrease of 
BMD after total thyreoidectomy and subsequent suppressive therapy. Although TC 
comprises only 1. 1 – 1. 9% of all cancers it is the most frequent endocrine tumor making 
around 90% of them. It is 3-times  more frequent in women than in men. The most frequent 
types are well-differentiated cancers – papillary (80 – 85%) and less frequent follicular (5 – 
10%) thyroid carcinoma.  
The standard therapy of thyroid carcinomas (TC) consists of total or nearly total 
thyroidectomy. Then the  whole-life substitution therapy  by oral thyroxine (T4) is given. 
Another goal of this therapy is to suppress serum thyroid stimulating hormone  (TSH) to 
prevent the growth factor-like effect of TSH on well-differentiated TC cells. The 
recommendation is to administer supraphysiologic amounts of oral T4. This leads to 
hyperthyroidism, which is subclinical. The influence of thyroid hormones on bone tissue is 
well known (Altabas et al., 2007). In hyperthyreosis the acitivty of osteoblasts and 
osteoclasts is increased, but the influence of osteoclasts is dominating leading to bone 
resorption and osteoporosis. The longstanding subclinical hyperthyroidism may result in 
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increased bone turnover and decreased bone mineral density (BMD). The aim of the study 
was to assign the damage of bone metabolism in TC patients.  
4.2 Patients and methods 
Bone mineral density (BMD) was measured by dual energy photon x-ray absorptiometry 
BMD using osteodenzitometer Holgic Discovery in the lumbar spine and hips. In cases with 
arteficialy increased bone density caused by degenerative bone changes we measured BMD 
also in forearm. BMD was classified using T score  in postmenopausal women and more 
than 50 years old men . We classified Z score in premenopausal women and younger than 
50 years men. C-terminal cross -linked telopeptides of type I collagen (CTX) were measured 
using ELISA. Additionally serum TSH and fT4 (free T4) were measured. Relationships 
between baseline characteristics (age, menopausal status in women, TSH levels and 
duration of substitutional therapy) and BMD were assessed using univariate and 
multivariate analysis tools. 
Association between two nominal variables was tested using the Chi-squared test of 
independence. Association between an interval variable and a nominal one was tested using 
ANOVA or Kruskal-Wallis test, depending on the distribution of the interval variable; in 
case of a dichotomous variable, t-test was applied instead of ANOVA and Mann-Whitney 
test instead of Kruskal-Wallis test. A multiple linear regression was performed to test for 
association between an dependent interval variable and several predicting interval 
variables. 
We analysed BMD data from 165 TC patients after total tyroidectomy on supportive therapy 
in our study. There were 13 men and 152 women, 94 were postmenpausal (postMP), 44 
premenopausal (preMP), in 14 the menopausal sattus was unknown. The mean age was 51 
years. Age characteristics are in table 3. 
 
 
Age characteristics: 
 All Men PostMP women PreMP women 
Min 21 29 34 21 
Max 78 77 78 55 
Mean 53 49 59 39 
Median 54 50 58 41 
Standard deviation 12.65 14.21 8.25 8.45 
 
Table 3. Age characteristics 
4.3 Results 
We included 165 TC patients in the study. There were 13 men a 152  women, the mean 
duration of thyroid suppressive  therapy was 7. 2 years (0 – 24 years). The patients exhibit 
osteporosis in 31%, 39% had osteopenia, whereas 30% had normal BMD (fig. 12).  
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Fig. 12. BMD in TC patients 
The BMD changes were localised in different sites (fig. 13) 
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Fig. 13. Localisations of BMD decresae in TC paients 
The incidence of osteoporosis appeared to increase with age but did not correlated with 
duration of  thyroid suppressive  therapy (fig. 14) 
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Fig. 14. Duration of suppressive therapy and BMD 
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We confiirmed higher incidence of osteoporosis in postMP women and in the small 
subgroup of postMP women on antiporotic therapy we confirmed efficacy of this therapy 
(fig.15). But the gorup  was very small and we cannot make any conclusuions. 
 
 
 
 
Comparison of BMD changes in controlled group of patients 
with/without antiresorptive therapy (p=0.062) 
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Fig. 15. Comparison of BMD changes in controlled group with/without antiresorpitve 
therapy 
We confirmed 10 pathological fractures in our study (tab. 4) 
 
 
Fractures 
10 pathological fractures 
Site 
 wrist  3 
 spine  3 
 others 4 
 
Table 4. Pathological fractures  in TC patients 
The pathological fractures were in correlation with decreased BMD to osteopenia or 
osteoporosis (fig. 16) 
 Normal BMD 
 Osteopenia 
 Osteoporosis  
Without antiresorptive therapy 
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Fig. 16. BMD and compressive fractures in TC patients 
4.4 Discussion 
Published data on this topic are scarce and conflicting. Some of them did not prove 
correlation between subclinical hyperthyreosis and decrease in BMD (S. I. Greenspan & F. S. 
Greenspan, 2005). Others  have found, that if suppressive therapy does not suppress the 
TSH below normal value it does not decrease BMD and does not worsen the prognosis of 
TC (Biondi & Cooper, 2010). Similar results were published also in  the past (Shomon, 1995). 
Some on the other hand has confirmed that  long term suppressive therapy affects bone 
turnover and bone mineral density in pre and postmenopausal women with TC 
(Heijekmann et al., 2005). Decrese in BMD as a result of suppressive therapy in TC was 
confirmed but this effect was ameliorated by preventive substitution of calcium and 
calcitonin  (Mikosch et al., 2006). In this metaanalysis of 8 studies the influence of thyreoidal 
suppression on BMD in postmenopausal women was confirmed. It was not confirmed in 
men and premenopausal women. The limitation was a substantial inhomogeneity of 
patients groups and uneveness in calcium supplementation.  
4.5 Conclusions and future directions 
The long term survivors from TC after total thyroidectomy  on  thyroid suppressive  therapy 
have higher risk of osteoporosis and therefore we recommend BMD testing and appropriate 
measures according to results. The BMD decrease may be a risk factor for pathological 
fractures and as the TC has very good prognosis, it does matter (B. Špániková.& S. Špánik, 
2011) 
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